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Summary There is emerging evidence to support the efﬁcacy of some antiepileptic
drug (AED) combinations in refractory epilepsy. Deﬁnitive clinical studies are, how-
ever, difﬁcult to perform. Experimental seizure models can be employed to identify
potentially useful combinations for subsequent clinical evaluation. We have investi-
gated the anticonvulsant effects of topiramate (TPM) in combination with 13 other
AEDs in the pentylenetetrazol (PTZ) and maximal electroshock (MES) seizure models.
Single drugs and combinations were administered by intraperitoneal injection and
anticonvulsant effects determined at 1-hour post-dosing. TPM was without signiﬁcant
effect in the PTZ test. In contrast, phenobarbital, primidone, ethosuximide, sodium
valproate, felbamate and tiagabine all increased the latency to the ﬁrst generalised
seizure. Combinations of TPM and active adjunctive drug were universally effective.
Combinations of TPM with clobazam, lamotrigine and levetiracetam were also anti-
convulsant, despite the inactivity of the constituent compounds when administered
alone. TPM reduced the incidence of MES-induced seizures in a dose-dependent man-
ner, as did phenobarbital, phenytoin, primidone, carbamazepine, sodium valproate,
clobazam, lamotrigine, felbamate and tiagabine. All combination treatments were
similarly effective. These ﬁndings suggest that combinations of TPM with lamotrig-
ine and levetiracetam may demonstrate anticonvulsant synergism and merit further
investigation in additional model systems and with recourse to more quantitative
mathematical analysis.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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Introduction
Monotherapy has been the gold standard of
antiepileptic drug (AED) treatment for over 20
years1,2. In contrast, polypharmacy has tradition-
ally been fraught with poor tolerability, compli-
cated pharmacokinetic interactions and a greater
propensity for cognitive impairment2,3. Recent
evidence suggests that monotherapy affords symp-
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tomatic relief from seizures in only around 60%
of people with epilepsy4. While a further 3—5% of
patients may beneﬁt from combination treatment
with two or more AEDs, there remains a signiﬁcant
population of treated patients who continue to
experience seizures.
Current wisdom suggests that addressing the
problem of refractory epilepsy requires the in-
troduction of novel AEDs, with similarly novel
mechanisms of action, for use as monotherapy and
the development of a rational approach to treat-
ment which also embraces the potential beneﬁts
of polypharmacy. In the last decade of the 20th
century, nine new antiepileptic agents reached
the global marketplace5. Simpler pharmacokinet-
ics, lesser propensity for interactions and more
favourable side-effect proﬁles render them more
suitable for use in combination regimens than
their predecessors6,7. With this welcome expan-
sion of the pharmacological armamentarium, ra-
tional polypharmacy for epilepsy may be a realistic
possibility8—10.
Although there is emerging data to endorse the
use of some AED combinations in the treatment of
refractory epilepsy11—15, deﬁnitive evidence sup-
porting efﬁcacy of particular polypharmacy regi-
mens is difﬁcult to obtain. It requires a quanti-
tative assessment of the antiepileptic effect and
dose-related side effects of single drugs and com-
binations in relatively homogeneous populations of
epileptic patients. It may be possible to circumvent
these difﬁculties by the use of experimental seizure
models to determine the potential protective in-
dices of AED combinations16.
Topiramate (TPM) is a contemporary AED with
multiple mechanisms of action and efﬁcacy in
a wide range of experimental seizure models17.
Despite limited evidence to support its use in
particular polypharmacy regimens12,18—20, TPM is
licensed world-wide as adjunctive treatment for
a broad spectrum of seizure types and epilepsy
syndromes5,21. In an attempt to identify optimum
combinations for further clinical evaluation, we
have investigated pharmacodynamic interactions
between TPM and a series of traditional and modern
AEDs in the pentylenetetrazol (PTZ) and maximal
electroshock (MES) seizure models in mice.
Methods
Animals
Adult male ICR mice (25—30 g) were obtained from
Harlan Olac (Bicester, UK) and housed in a con-
trolled temperature and humidity environment with
day/night cycle conditions and access to food and
water ad libitum. Animals were kept for a minimum
period of 7 days prior to use to allow for acclimati-
sation. All experimental work was governed by the
Animals (Scientiﬁc Procedures) Act, 1986 (UK).
Reagents
All chemicals (reagent grade), PTZ, and the estab-





methylsuccinimide), sodium valproate (2-propyl-
pentanoic acid) and clobazam (7-chloro-1-methyl-
5 - phenyl-1H-1,5-benzodiazepine-2,4-[3H,5H]-dio-
ne) were obtained from the Sigma Chemical
Company (Poole, UK). New AEDs were obtained
from the following sources: vigabatrin (d,l-4-amino-
hex-5-enoic acid)–—Hoechst Marion Roussel (Uxbri-
dge, UK); lamotrigine (6-(2,3-dichlorophenyl)-1,2,
4-triazine-3,5-diamine)–—GlaxoWellcome Research
and Development (Stevenage, UK); felbamate
(2-phenyl-1,3-propanediol dicarbamate)–—Schering-
Plough Research Institute (Kenilworth, NJ, USA);
gabapentin (1-(aminomethyl)-cyclohexaneacetic
acid)–—Parke-Davis Pharmaceutical Research (Ann
Arbor, MI, USA); TPM (2,3:4,5-bis-O-(1-methylethyl-
idene)--d-fructopyranose sulphamate)–—The RW
Johnson Pharmaceutical Research Institute (Spring
House, PA, USA); tiagabine ((R)-(−)-1-[4,4-bis(3-
methyl-2-thienyl)-3-butenyl]-3 - piperidine - carbo-
xylic acid, hydrochloride)–—Novo Nordisk A/S
(Bagsvaerd, Denmark); levetiracetam ((S)--ethyl-
2-oxo-pyrrolidine acetamide)–—UCB Pharma (Chemin
du Foriest, Belgium).
Drug administration
All drugs were prepared daily for intraperitoneal
(i.p.) injection. Phenobarbital, phenytoin, primi-
done, carbamazepine and TPM were prepared as a
suspension in 0.5% Tween 80 (polyoxyethylene sor-
bitan monooleate). Felbamate was suspended in
30% polyethylene glycol 400. All other agents were
dissolved in 0.9% saline.
Study design
All experiments were designed to include a con-
trol group, three single dose TPM groups (5, 25
and 125mg/kg), three single dose adjunctive drug
groups (low, medium and high dose) and nine fur-
ther groups encompassing all possible combinations
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5 Drug X (low dose)
6 Drug X (medium dose)
7 Drug X (high dose)
8 Drug X (low dose) + TPM (5mg/kg)
9 Drug X (medium dose) + TPM (5mg/kg)
10 Drug X (high dose) + TPM (5mg/kg)
11 Drug X (low dose) + TPM (25mg/kg)
12 Drug X (medium dose) + TPM (25mg/kg)
13 Drug X (high dose) + TPM (25mg/kg)
14 Drug X (low dose) + TPM (125mg/kg)
15 Drug X (medium dose) + TPM (125mg/kg)
16 Drug X (high dose) + TPM (125mg/kg)
Drug X = adjunctive drug (see Table 2 for appropriate
doses).










Phenobarbital (PB) 2 10 50
Phenytoin (PHT) 2 10 50
Primidone (PRM) 4 20 100
Carbamazepine (CBZ) 2 10 50
Ethosuximide (ESM) 25 125 625
Sodium valproate (VPA) 40 200 1000
Clobazam (CLB) 0.2 1 5
Vigabatrin (VGB) 10 50 250
Lamotrigine (LTG) 0.5 2.5 12.5
Felbamate (FBM) 10 50 250
Gabapentin (GBP) 5 25 125
Tiagabine (TGB) 0.2 1 5
Levetiracetam (LEV) 10 50 250
of TPM and adjunctive drug (Tables 1 and 2). PTZ
studies employed six mice per treatment group,
while MES studies used 10 animals per group.
Pentylenetetrazol test
At 1-hour post-dosing, mice were administered
85mg/kg PTZ (37 ◦C; in 0.9% saline) by subcuta-
neous (s.c.) injection and the time to the ﬁrst
generalised seizure with loss of the righting reﬂex
was recorded in individual animals22. Experiments
were conducted in a blinded manner (observers;
GGT & EB). An arbitrary cut-off time of 15minutes
was assigned for non-responsive animals.
Maximal electroshock test
At 1-hour post-dosing, mice were subjected to
the MES test22. Constant current electroshock
stimuli were delivered via auricular electrodes
from an ECT unit (Ugo Basile 7800, Comerio,
Italy). MES stimuli, comprising 0.2 seconds of rect-
angular positive pulses (50mA at 60Hz; pulse
width = 0.4milliseconds), were pre-determined to
induce 100% tonic seizures in a group of na¨ıve an-
imals. The percentage of animals exhibiting tonic
hind-limb extension in each treatment group was
recorded. Experiments were again conducted in a
blinded manner (observer; GGT).
Statistical analysis
Analysis was performed using MINITAB for Windows
statistical package (Version 10.1) on a Viglen Con-
tender ATX P5/166MMXmicrocomputer. PTZ seizure
data were expressed as the mean time (seconds)
to the ﬁrst generalised seizure in each treatment
group and compared to control by one-way ANOVA
with a Dunnett correction for multiple comparisons.
MES seizure data were expressed as the percentage
of animals exhibiting tonic hind-limb extension in
each treatment group and compared to control with




In the PTZ studies, TPM was without anticonvul-
sant effect (Table 3). Of the adjunctive agents
investigated, single doses of phenobarbital, primi-
done, ethosuximide, sodium valproate, felbamate
and tiagabine all signiﬁcantly (P < 0.05) increased
the latency to PTZ-induced seizures when com-
pared to control (Table 3). When combined with
TPM, these active agents were similarly effective
(Table 3). Combinations of TPM with clobazam
(Fig. 1), lamotrigine (Fig. 2) and levetiracetam
(Fig. 3) afforded signiﬁcant (P < 0.05) protection
against PTZ-induced seizures, despite inactivity of
the constituent agents when administered alone.
Maximal electroshock studies
In the MES studies, TPM signiﬁcantly (P < 0.05)
reduced the incidence of tonic hind-limb exten-
sion when compared to control (Table 4). Of the







Table 3 The latency to the ﬁrst generalised seizure induced by 85mg/kg PTZ at 1 hour after treatment with TPM and/or adjunctive drug (see Tables 1 and 2
for deﬁnition of treatment groups) in groups (n = 6) of mice.
Adjunctive
drug
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Group 9 Group 10 Group 11 Group 12 Group 13 Group 14 Group 15 Group 16
PB 456 (102) 545 (69) 449 (120) 381 (104) 396 (43) 704 (92) 900 (0)∗ 506 (58) 864 (36)∗ 900 (0)∗ 514 (92) 821 (79)∗ 900 (0)∗ 622 (151) 893 (7)∗ 900 (0)∗
PHT 322 (65) 381 (136) 360 (99) 434 (58) 383 (62) 309 (63) 365 (115) 299 (73) 439 (83) 415 (125) 388 (72) 421 (56) 401 (99) 328 (122) 453 (125) 407 (102)
PRM 358 (137) 383 (32) 321 (84) 413 (129) 469 (122) 723 (109) 900 (0)∗ 391 (109) 291 (43) 619 (120) 442 (121) 440 (110) 718 (87) 659 (165) 750 (103) 821 (79)∗
ESM 398 (72) 347 (88) 463 (128) 357 (33) 451 (45) 558 (135) 900 (0)∗ 376 (50) 556 (104) 900 (0)∗ 393 (131) 643 (139) 900 (0)∗ 349 (73) 677 (114) 900 (0)∗
CBZ 269 (68) 351 (85) 319 (43) 385 (176) 432 (110) 334 (90) 318 (108) 444 (11) 459 (146) 491 (169) 372 (115) 333 (27) 563 (136) 376 (94) 384 (95) 676 (130)
VPA 341 (117) 336 (54) 342 (117) 457 (149) 389 (113) 603 (124) 900 (0)∗ 395 (177) 498 (204) 824 (76)∗ 559 (166) 601 (183) 900 (0)∗ 596 (98) 649 (114) 900 (0)∗
CLB 316 (80) 236 (15) 310 (79) 360 (107) 417 (93) 617 (137) 648 (120) 416 (97) 763 (92)∗ 840 (60)∗ 537 (147) 788 (74)∗ 900 (0)∗ 318 (35) 748 (100)∗ 900 (0)∗
VGB 420 (114) 378 (143) 423 (62) 378 (56) 451 (141) 468 (119) 436 (100) 544 (137) 448 (124) 458 (76) 522 (171) 541 (130) 467 (72) 507 (149) 564 (82) 505 (97)
LTG 385 (37) 427 (40) 377 (65) 461 (62) 403 (76) 396 (60) 629 (87) 396 (74) 481 (58) 766 (53)∗ 358 (22) 486 (53) 765 (85)∗ 434 (70) 790 (64)∗ 849 (38)∗
GBP 412 (84) 399 (88) 431 (107) 391 (67) 319 (13) 522 (101) 357 (93) 349 (78) 622 (200) 526 (134) 464 (25) 522 (162) 720 (114) 499 (37) 673 (133) 726 (93)
FBM 344 (122) 392 (54) 303 (49) 479 (73) 526 (210) 821 (79)∗ 858 (42)∗ 489 (103) 723 (70)∗ 685 (83)∗ 374 (69) 766 (132)∗ 762 (100)∗ 635 (74) 736 (110)∗ 862 (38)∗
TGB 450 (112) 403 (11) 408 (34) 520 (125) 505 (49) 896 (4)∗ 900 (0)∗ 433 (72) 808 (93) 900 (0)∗ 450 (46) 900 (0)∗ 900 (0)∗ 453 (144) 900 (0)∗ 900 (0)∗
LEV 345 (58) 305 (92) 427 (106) 380 (40) 351 (142) 429 (60) 438 (81) 392 (48) 461 (154) 638 (89) 489 (14) 722 (86) 879 (21)∗ 599 (168) 790 (71)∗ 900 (0)∗
Results are expressed as the mean time in seconds (±SEM). Statistical signiﬁcance (∗P < 0.05) was determined by one-way ANOVA with Dunnett correction for
multiple comparisons.
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Figure 1 Effect of TPM (5, 25, 125mg/kg) and clobazam (CLB; 0.2, 1, 5mg/kg) administered alone and in combination
on the latency to the ﬁrst generalised seizure induced by 85mg/kg PTZ at 1 hour post-administration. Results (n = 6)
are expressed as the mean of absolute values and error bars denote the SEM. Statistical signiﬁcance (∗P < 0.05) was
determined by one-way ANOVA with Dunnett correction for multiple comparisons.
phenobarbital, phenytoin, primidone, carbamaze-
pine, sodium valproate, clobazam, lamotrigine, fel-
bamate and tiagabine signiﬁcantly (P < 0.05) pro-
tected against MES-induced seizures (Table 4). All
combination treatments were effective in the MES
model (Table 4).
Figure 2 Effect of TPM (5, 25, 125mg/kg) and lamotrigine (LTG; 0.5, 2.5, 12.5mg/kg) administered alone and in
combination on the latency to the ﬁrst generalised seizure induced by 85mg/kg PTZ at 1 hour post-administration.
Results (n = 6) are expressed as the mean of absolute values and error bars denote the SEM. Statistical signiﬁcance
(∗P < 0.05) was determined by one-way ANOVA with Dunnett correction for multiple comparisons.
Discussion
Although new AEDs are almost exclusively intro-
duced as adjunctive treatment, there is only lim-
ited evidence to support the use of speciﬁc drug
combinations13. In the absence of convincing clini-
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Figure 3 Effect of TPM (5, 25, 125mg/kg) and levetiracetam (LEV; 10, 50, 250mg/kg) administered alone and in
combination on the latency to the ﬁrst generalised seizure induced by 85mg/kg PTZ at 1 hour post-administration.
Results (n = 6) are expressed as the mean of absolute values and error bars denote the SEM. Statistical signiﬁcance
(∗P < 0.05) was determined by one-way ANOVA with Dunnett correction for multiple comparisons.
cal data, experimental seizure models can be em-
ployed to identify potentially useful polypharmacy
regimens for further patient-based evaluation16.
We have explored potential pharmacodynamic in-
teractions between TPM and a number of tradi-
tional and contemporary AEDs in the PTZ and MES
seizure models.
In keeping with previous investigations17,18, sin-
gle dose TPM was without effect on the latency
to PTZ-induced seizures. In contrast, several ad-
junctive agents including phenobarbital, primi-
done, ethosuximide, sodium valproate, felbamate
and tiagabine all had signiﬁcant anticonvulsant
effects when administered alone. These ﬁndings
were anticipated on the basis of prior studies23—25,
although the inactivity of clobazam in the PTZ
model was unexpected. Combinations of TPM with
active adjunctive agents were universally effec-
tive, suggesting the absence of any infra-additive
efﬁcacy. Furthermore, when TPM was combined
with clobazam, lamotrigine and levetiracetam,
anticonvulsant effects in the PTZ model were ob-
served, despite the inactivity of the constituent
compounds.
Anticonvulsant synergism with combinations of
TPM and lamotrigine in the PTZ model has been
reported previously12, although the basis for this
apparent interaction remains unclear. TPM is ac-
tive in the PTZ threshold test25, and while neither
TPM nor lamotrigine is sufﬁciently powerful to
prevent supra-maximal PTZ seizures when admin-
istered alone, their combined efﬁcacy on seizure
threshold may provide otherwise obscured protec-
tion. A similar situation may prevail when TPM is
combined with levetiracetam, which like TPM has
no recognised efﬁcacy in the supra-maximal PTZ
test, but does elevate the PTZ seizure threshold26.
In both cases, however, pharmacokinetic interac-
tion cannot be ruled out, although none would be
anticipated on the basis of published data6. The
evidence for synergism between TPM and clobazam
is considerably less convincing, given the widely
recognised efﬁcacy of benzodiazepines in the PTZ
model23. While it is possible that the addition of
TPM, even at the lowest dose, helped unmask the
anticipated activity of clobazam, it is difﬁcult to
reconcile this relative insensitivity in a series of
PTZ studies which otherwise followed convention
in terms of AED efﬁcacy.
In the MES model, TPM produced a dose-depen-
dent reduction in the incidence of tonic seizures
when administered alone. This ﬁnding was con-
sistent with those of previous investigations17,18.
The majority of adjunctive treatments, with the
exception of ethosuximide, vigabatrin, gabapentin
and levetiracetam, also had protective effects
against MES-induced seizures following single dose
administration. Again, these observations were
largely as expected23—25, although the activity of









Table 4 The incidence of tonic hind-limb extension induced by MES at 1 hour after treatment with TPM and/or adjunctive drug (see Tables 1 and 2 for deﬁnition
of treatment groups) in groups (n = 10) of mice.
Adjunctive
drug
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Group 9 Group 10 Group 11 Group 12 Group 13 Group 14 Group 15 Group 16
PB 100 100 60 10∗ 90 70 0∗ 90 70 0∗ 40 30∗ 0∗ 0∗ 0∗ 0∗
PHT 100 90 40 10∗ 80 50 0∗ 50 40 10∗ 10∗ 20∗ 0∗ 10∗ 0∗ 10∗
PRM 90 90 60 30 70 20∗ 0∗ 60 40 0∗ 50 10∗ 0∗ 20∗ 0∗ 10∗
ESM 80 90 40 40 100 70 100 80 80 80 40 60 30 20∗ 30 10∗
CBZ 100 80 50 0∗ 70 40 10∗ 30∗ 20∗ 0∗ 10∗ 0∗ 0∗ 0∗ 0∗ 0∗
VPA 100 100 60 10∗ 90 60 0∗ 60 70 10∗ 60 30∗ 20∗ 20∗ 30∗ 0∗
CLB 90 60 50 20∗ 90 60 20∗ 30 40 30 40 20∗ 20∗ 20∗ 0∗ 0∗
VGB 80 70 40 20∗ 90 70 80 60 30 50 40 40 20∗ 10∗ 0∗ 10∗
LTG 100 90 50 10∗ 90 60 0∗ 30∗ 30∗ 0∗ 20∗ 0∗ 10∗ 0∗ 10∗ 0∗
GBP 90 80 60 30 100 70 80 60 80 50 50 30 40 20∗ 40 0∗
FBM 100 80 50 10∗ 60 10∗ 10∗ 30∗ 0∗ 0∗ 30∗ 0∗ 10∗ 0∗ 0∗ 0∗
TGB 100 80 30∗ 0∗ 90 80 50 50 60 30∗ 30∗ 10∗ 20∗ 10∗ 0∗ 0∗
LEV 90 80 50 0∗ 90 90 90 60 40 10∗ 20∗ 30 0∗ 0∗ 20∗ 0∗
Results are expressed as the absolute percentage incidence in each group. Statistical signiﬁcance (∗P < 0.05) was determined by Fisher’s exact test with Bonferroni
correction for multiple comparisons.
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With the efﬁcacy of TPM, and a preponderance of
active compounds, combination treatment in the
MES model was universally effective. Accordingly,
this arm of the investigation revealed little with
regard to potential pharmacodynamic interactions,
although it did again suggest the absence of antag-
onism or infra-additive efﬁcacy between TPM and
other active agents.
Although this investigation revealed few posi-
tive or unanticipated results, there is emerging
experimental evidence to support the efﬁcacy of
particular combinations of established and new
AEDs. Isobolographic analysis has revealed poten-
tial synergism between gabapentin and a variety
of agents28 and a speciﬁc interaction between ox-
carbazepine and clonazepam29. A further study in
the 4-aminopyridine model has suggested potential
beneﬁts of combining felbamate and lamotrigine30.
These investigations employed measures of both
efﬁcacy and toxicity and incorporated drug analysis
to eliminate the potential interference of pharma-
cokinetic interactions. Similarly detailed studies
with TPM have been reported19,20. Sub-effective
doses of TPM potentiated the anticonvulsant ef-
fects of phenobarbital, phenytoin and sodium
valproate in the MES model without increasing
toxicity or inﬂuencing AED pharmacokinetics19.
Further investigations with TPM identiﬁed a phar-
macodynamic interaction with phenobarbital and
sodium valproate in the amygdala-kindled rat and
with ethosuximide in the PTZ test20.
In the interests of simplicity, the current study
relied on the subjective assessment of pharmaco-
dynamic interactions, without recourse to detailed
mathematical analysis of the data. As such, the
ﬁndings were compromised when one or both con-
stituent compounds was active in the chosenmodel.
This was particularly evident in the MES test where
TPM was effective and, accordingly, all combina-
tions were effective. The probability of identify-
ing supra-additive or synergistic combinations was
therefore limited and, in most cases, interactions
could be regarded as no more than additive. Fur-
thermore, without conducting a concurrent inves-
tigation of the potential neurotoxicity of combina-
tion treatments or ruling out the potential interfer-
ence of pharmacokinetic interactions, it is difﬁcult
to ascribe true pharmacodynamic synergism to any
of the combination treatments assessed. Finally,
with the use of acute drug administration and a
groundswell of opinion which suggests that the PTZ
and MES models are not sufﬁciently representative
of the clinical condition, the impact of this investi-
gationmay be limitedwithout further investigation.
In conclusion, this study investigated pharma-
codynamic interactions between TPM and a num-
ber of traditional and contemporary AEDs as an
antecedent to identifying candidate drug com-
binations in the laboratory without resorting to
complex, expensive and time-consuming clinical
screening. The study design and model systems em-
ployed did not facilitate sufﬁcient discrimination
between positive results and, in the majority of
cases, interactions could be regarded as additive
at best. However, despite additional shortcom-
ings common to many pre-clinical studies, speciﬁc
combinations of TPM with lamotrigine and leve-
tiracetam were identiﬁed and these clearly merit
further detailed investigation for the treatment of
refractory epilepsy.
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